annual cash & cash equivalents:
$755.99M+$317.13M(+72.26%)Summary
- As of today (August 31, 2025), ACAD annual cash & cash equivalents is $755.99 million, with the most recent change of +$317.13 million (+72.26%) on December 31, 2024.
- During the last 3 years, ACAD annual cash & cash equivalents has risen by +$235.29 million (+45.19%).
- ACAD annual cash & cash equivalents is now at all-time high.
Performance
ACAD Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$762.00M+$80.42M(+11.80%)Summary
- As of today (August 31, 2025), ACAD quarterly cash & cash equivalents is $762.00 million, with the most recent change of +$80.42 million (+11.80%) on June 30, 2025.
- Over the past year, ACAD quarterly cash & cash equivalents has increased by +$261.05 million (+52.11%).
- ACAD quarterly cash & cash equivalents is now at all-time high.
Performance
ACAD quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
ACAD Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +72.3% | +52.1% |
| 3 y3 years | +45.2% | +74.6% |
| 5 y5 years | +8.4% | +15.7% |
ACAD Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +81.4% | at high | +120.3% |
| 5 y | 5-year | at high | +81.4% | at high | +120.3% |
| alltime | all time | at high | >+9999.0% | at high | >+9999.0% |
ACAD Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2025 | - | $762.00M(+11.8%) |
| Mar 2025 | - | $681.58M(-9.8%) |
| Dec 2024 | $755.99M(+72.3%) | $755.99M(+33.7%) |
| Sep 2024 | - | $565.33M(+12.9%) |
| Jun 2024 | - | $500.94M(+6.5%) |
| Mar 2024 | - | $470.52M(+7.2%) |
| Dec 2023 | $438.87M(+5.3%) | $438.87M(+26.9%) |
| Sep 2023 | - | $345.92M(-7.8%) |
| Jun 2023 | - | $375.38M(-6.8%) |
| Mar 2023 | - | $402.87M(-3.3%) |
| Dec 2022 | $416.82M(-20.0%) | $416.82M(-4.5%) |
| Sep 2022 | - | $436.58M(+0.1%) |
| Jun 2022 | - | $436.35M(-2.2%) |
| Mar 2022 | - | $445.98M(-14.4%) |
| Dec 2021 | $520.71M(-17.6%) | $520.71M(-3.6%) |
| Sep 2021 | - | $540.29M(-3.0%) |
| Jun 2021 | - | $556.92M(-3.6%) |
| Mar 2021 | - | $577.77M(-8.6%) |
| Dec 2020 | $631.96M(-9.4%) | $631.96M(-1.9%) |
| Sep 2020 | - | $644.44M(-2.1%) |
| Jun 2020 | - | $658.55M(+1.1%) |
| Mar 2020 | - | $651.41M(-6.6%) |
| Dec 2019 | $697.43M(+47.3%) | $697.43M(+2.0%) |
| Sep 2019 | - | $683.85M(+79.1%) |
| Jun 2019 | - | $381.89M(-7.8%) |
| Mar 2019 | - | $414.32M(-12.5%) |
| Dec 2018 | $473.52M | $473.52M(+121.1%) |
| Sep 2018 | - | $214.14M(-16.6%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2018 | - | $256.86M(-13.8%) |
| Mar 2018 | - | $298.06M(-12.7%) |
| Dec 2017 | $341.34M(-35.5%) | $341.34M(-6.9%) |
| Sep 2017 | - | $366.63M(-12.1%) |
| Jun 2017 | - | $417.32M(-11.1%) |
| Mar 2017 | - | $469.48M(-11.3%) |
| Dec 2016 | $529.04M(+145.9%) | $529.04M(-10.2%) |
| Sep 2016 | - | $588.86M(+42.7%) |
| Jun 2016 | - | $412.56M(-9.8%) |
| Mar 2016 | - | $457.24M(+112.5%) |
| Dec 2015 | $215.13M(-33.3%) | $215.13M(-10.6%) |
| Sep 2015 | - | $240.69M(-11.1%) |
| Jun 2015 | - | $270.78M(-9.1%) |
| Mar 2015 | - | $297.89M(-7.6%) |
| Dec 2014 | $322.49M(+73.6%) | $322.49M(-4.5%) |
| Sep 2014 | - | $337.80M(-4.7%) |
| Jun 2014 | - | $354.45M(-4.0%) |
| Mar 2014 | - | $369.29M(+98.8%) |
| Dec 2013 | $185.79M(+72.1%) | $185.79M(-5.3%) |
| Sep 2013 | - | $196.18M(-4.5%) |
| Jun 2013 | - | $205.45M(+102.5%) |
| Mar 2013 | - | $101.46M(-6.0%) |
| Dec 2012 | $107.97M(+103.8%) | $107.97M(+368.2%) |
| Sep 2012 | - | $23.06M(+8.0%) |
| Jun 2012 | - | $21.35M(-17.6%) |
| Mar 2012 | - | $25.92M(+15.2%) |
| Mar 2004 | - | $22.49M(+256.6%) |
| Dec 2003 | $52.98M(+1089.6%) | $6.31M |
| Dec 2002 | $4.45M | - |
FAQ
- What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
- What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents year-on-year change?
- What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
- What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents year-on-year change?
What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents?
The current annual cash & cash equivalents of ACAD is $755.99M
What is the all time high annual cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals Inc. all-time high annual cash & cash equivalents is $755.99M
What is ACADIA Pharmaceuticals Inc. annual cash & cash equivalents year-on-year change?
Over the past year, ACAD annual cash & cash equivalents has changed by +$317.13M (+72.26%)
What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of ACAD is $762.00M
What is the all time high quarterly cash & cash equivalents for ACADIA Pharmaceuticals Inc.?
ACADIA Pharmaceuticals Inc. all-time high quarterly cash & cash equivalents is $762.00M
What is ACADIA Pharmaceuticals Inc. quarterly cash & cash equivalents year-on-year change?
Over the past year, ACAD quarterly cash & cash equivalents has changed by +$261.05M (+52.11%)